Presentation is loading. Please wait.

Presentation is loading. Please wait.

2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions Tom Sutula, MD, PhD Department of Neurology, University.

Published byJewel Banks Modified over 9 years ago

Similar presentations

Presentation on theme: "2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions Tom Sutula, MD, PhD Department of Neurology, University."— Presentation transcript:

1 2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions Tom Sutula, MD, PhD Department of Neurology, University of Wisconsin Chief Scientific Officer, NeuroGenomex, Inc.

2 cannot undergo isomerization The novel mechanism of 2DG: why 2DG is a glycolytic inhibitor

3 Completed preclinical efficacy studies Animal Models of Acute & Chronic Epilepsy in vitro Models of Seizure Induction  protection against seizures evoked by 6Hz stimulation  protection against audiogenic seizures in Fring’s mice  2-fold slowing of latency to status epilepticus onset by kainic acid, pilo  2-fold slowing of kindling progression evoked from different brain sites  time course of action & dose range  effective against seizure progression when administered up to 10 minutes after a seizure 2DG reduces epileptic discharges evoked by:  K + (7.5mM, ictal & interictal)  bicuculline (GABA antagonist)  4AP (K + channel antagonist)  DHPG (metabotropic glutamate agonist )

4 Completed preclinical efficacy studies Animal Models of Acute & Chronic Epilepsy in vitro Models of Seizure Induction  these properties are unlike ANY other marketed drugs  2DG is disease- modifying against progressive adverse effects of seizures  efficacy studies support clinical utility for both ACUTE and CHRONIC uses 2DG reduces epileptic discharges evoked by:  K + (7.5mM, ictal & interictal)  bicuculline (GABA antagonist)  4AP (K + channel antagonist)  DHPG (metabotropic glutamate agonist )  protection against seizures evoked by 6Hz stimulation  protection against audiogenic seizures in Fring’s mice  2-fold slowing of latency to status epilepticus onset by kainic acid, pilo  2-fold slowing of kindling progression evoked from different brain sites  time course of action & dose range  effective against seizure progression when administered up to 10 minutes after a seizure  implies that actions of 2DG at the cellular level are “broad- spectrum” against different mechanisms of network synchronization

5 Completed preclinical efficacy studies Animal Models of Acute & Chronic Epilepsy in vitro Models of Seizure Induction  implies that actions of 2DG at the cellular level are “broad- spectrum” against different mechanisms of network synchronization  these properties are unlike ANY other marketed drugs  2DG is disease- modifying against progressive adverse effects of seizures  efficacy studies support clinical utility for both ACUTE and CHRONIC uses 2DG reduces epileptic discharges evoked by:  K + (7.5mM, ictal & interictal)  bicuculline (GABA antagonist)  4AP (K + channel antagonist)  DHPG (metabotropic glutamate agonist )  protection against seizures evoked by 6Hz stimulation  protection against audiogenic seizures in Fring’s mice  2-fold slowing of latency to status epilepticus onset by kainic acid, pilo  2-fold slowing of kindling progression evoked from different brain sites  time course of action & dose range  effective against seizure progression when administered up to 10 minutes after a seizure

6 Completed preclinical efficacy studies Animal Models of Acute & Chronic Epilepsy in vitro Models of Seizure Induction  implies that actions of 2DG at the cellular level are “broad- spectrum” against different mechanisms of network synchronization  these properties are unlike ANY other marketed drugs  2DG is disease- modifying against progressive adverse effects of seizures  efficacy studies support clinical utility for both ACUTE and CHRONIC uses 2DG reduces epileptic discharges evoked by:  K + (7.5mM, ictal & interictal)  bicuculline (GABA antagonist)  4AP (K + channel antagonist)  DHPG (metabotropic glutamate agonist )  protection against seizures evoked by 6Hz stimulation  protection against audiogenic seizures in Fring’s mice  2-fold slowing of latency to status epilepticus onset by kainic acid, pilo  2-fold slowing of kindling progression evoked from different brain sites  time course of action & dose range  effective against seizure progression when administered up to 10 minutes after a seizure

7 Completed preclinical efficacy studies Animal Models of Acute & Chronic Epilepsy in vitro Models of Seizure Induction  implies that actions of 2DG at the cellular level are “broad- spectrum” against different mechanisms of network synchronization  these properties are unlike ANY other marketed drugs  2DG is disease- modifying against progressive adverse effects of seizures  efficacy studies support clinical utility for both ACUTE and CHRONIC uses 2DG reduces epileptic discharges evoked by:  K + (7.5mM, ictal & interictal)  bicuculline (GABA antagonist)  4AP (K + channel antagonist)  DHPG (metabotropic glutamate agonist )  protection against seizures evoked by 6Hz stimulation  protection against audiogenic seizures in Fring’s mice  2-fold slowing of latency to status epilepticus onset by kainic acid, pilo  2-fold slowing of kindling progression evoked from different brain sites  time course of action & dose range  effective against seizure progression when administered up to 10 minutes after a seizure

8 likely useful for acute epileptic conditons with ongoing seizures (eg., status epilepticus, clusters) potentially useful for peri- seizure administration to optimize delivery and minimize side-effects potentially novel methods of delivery in combination with stimulation /device therapies Implications for clinical applications 2DG delivery to neurons and circuits is activity-dependent: a novel advantageous property for an anticonvulsant 18F-2DG PET scan during status epilepticus H3-2DG autoradiogram during 1 hz stimulation 2DG is preferentially delivered to regions with high energy needs by activity-dependent neurovascular coupling involving neurons, glia, and endothelial cells in the “neurovascular unit”

9 likely useful for acute epileptic conditons with ongoing seizures (eg., status epilepticus, clusters) potentially useful for peri- seizure administration to optimize delivery and minimize side-effects potentially novel methods of delivery in combination with stimulation /device therapies Implications for clinical applications 2DG delivery to neurons and circuits is activity-dependent: a novel advantageous property for an anticonvulsant 18F-2DG PET scan during status epilepticus H3-2DG autoradiogram during 1 hz stimulation 2DG is preferentially delivered to regions with high energy needs by activity-dependent neurovascular coupling involving neurons, glia, and endothelial cells in the “neurovascular unit”

10 likely useful for acute epileptic conditons with ongoing seizures (eg., status epilepticus, clusters) potentially useful for peri- seizure administration to optimize delivery and minimize side-effects potentially novel methods of delivery in combination with stimulation /device therapies Implications for clinical applications 2DG delivery to neurons and circuits is activity-dependent: a novel advantageous property for an anticonvulsant 18F-2DG PET scan during status epilepticus H3-2DG autoradiogram during 1 hz stimulation 2DG is preferentially delivered to regions with high energy needs by activity-dependent neurovascular coupling involving neurons, glia, and endothelial cells in the “neurovascular unit”

11 likely useful for acute epileptic conditons with ongoing seizures (eg., status epilepticus, clusters) potentially useful for peri- seizure administration to optimize delivery and minimize side-effects potentially novel methods of delivery in combination with stimulation /device therapies Implications for clinical applications 2DG delivery to neurons and circuits is activity-dependent: a novel advantageous property for an anticonvulsant 18F-2DG PET scan during status epilepticus H3-2DG autoradiogram during 1 hz stimulation 2DG is preferentially delivered to regions with high energy needs by activity-dependent neurovascular coupling involving neurons, glia, and endothelial cells in the “neurovascular unit”

12 Activity-dependent effects of 2DG on synaptic transmission

13 Activity-dependent effects of 2DG on synaptic transmission no effects on synaptic properties in normal conditions

14 2DG reduces amplitude and frequency of sEPSCs after exposure to conditions that increase activity Activity-dependent effects of 2DG on synaptic transmission

15 modification in mEPSCs is activity-dependent implicates presynaptic vesicle release as a mechanism of action of 2DG Activity-dependent effects of 2DG on synaptic transmission NOT SHOWN: “homeostatic” effects on synaptic plasticity

16 2DG in the pipeline  PET imaging agent for 30+ years  Favorable toxicity history Completed Phase 1 in cancer More than 20 other investigator clinical studies with > 300 subjects Need to confirm safety in effective dose (ED) range – cardiac toxicity observed with chronic dosing at 10X > ED range, and mild potentially reversible cardiac autophagy in ED range  bioanalytical assay development, toxicity, PK, TK, ADME studies underway in 2010 Q2 Toxicology  distinctive pattern of effectiveness in pre-clinical models  disease-modifying against progressive adverse effects of seizures  novel acute and chronic anti- epilepsy mechanisms of action  2DG concentrates in areas of ictal epileptic activity Efficacy  IP licensed from WARF: 1 patent issued and 1 pending in US (has been issued in Australia)  NGX has exclusive license from WARF for all human therapeutic use Intellectual Property Remaining preclincal studies

17 2DG in the pipeline  PET imaging agent for 30+ years  Favorable toxicity history Completed Phase 1 in cancer More than 20 other investigator clinical studies with > 300 subjects Need to confirm safety in effective dose (ED) range – cardiac toxicity observed with chronic dosing at 10X > ED range, and mild potentially reversible cardiac autophagy in ED range  bioanalytical assay development, toxicity, PK, TK, ADME studies underway in 2010 Q2 Toxicology  distinctive pattern of effectiveness in pre-clinical models  disease-modifying against progressive adverse effects of seizures  novel acute and chronic anti- epilepsy mechanisms of action  2DG concentrates in areas of ictal epileptic activity Efficacy  IP licensed from WARF: 1 patent issued and 1 pending in US (has been issued in Australia)  NGX has exclusive license from WARF for all human therapeutic use Intellectual Property Remaining preclincal studies IND filing anticipated 2011 Q1

18 Current Development Plan Complete preclinical toxicity, formulation, CMC, and filing of IND “IND-enabling preclinical studies of 2DG for treatment of epilepsy” (awaiting NIH RAID, anticipated start Q2 2010) Will complete preclinical studies including bioanalytical assay development, pharmacokinetic, toxicological, toxicokinetic, manufacturing, formulation, and clinical trial designs, and regulatory documentation for submission of an IND. Investigator-initiated first in humans Phase I/II clinical trial in patients with intractable epilepsy “A Preliminary Tolerability and Efficacy Study of 2DG in Intractable Epilepsy” Nathan Fountain, MD, University of Virginia (EpilepsyTherapy Project-ERF, WARF, NGX, anticipated start in Q4 2010) This will be a preliminary study of 2DG that will seek to detect an efficacy signal and assess tolerability in 10-15 intractable patients with frequent seizures. Development of delayed release formulations Zeeh Experimental Pharmacy Station (University of Wisconsin) (E. Elder, PhD, supported by WARF) This program is developing delayed release formulations to exploit the activity-dependent uptake and short t 1/2 (~ 40 min) enabling chronic administration at lower total doses.

Download ppt "2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions Tom Sutula, MD, PhD Department of Neurology, University."

Similar presentations

Overview of the Keys to Successful Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. Tucson, Arizona October 18, 2001.

Overview of the Keys to Successful Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. Tucson, Arizona October 18, 2001.
The Drug Discovery Process

The Drug Discovery Process
I. high-fat, adequate-protein, low-carbohydrate diet. II. The diet forces the body to burn fats rather than carbohydrates. III. The original therapeutic.

I. high-fat, adequate-protein, low-carbohydrate diet. II. The diet forces the body to burn fats rather than carbohydrates. III. The original therapeutic.
Marc Bailie DVM, PhD Director In Vivo Facility Michigan State University, Chief Development Officer Integrated Nonclinical Development Solutions (INDS)

Marc Bailie DVM, PhD Director In Vivo Facility Michigan State University, Chief Development Officer Integrated Nonclinical Development Solutions (INDS)
AbstractSchema Conclusion Pharmacokinetic profile of the base-excision repair inhibitor Methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous.

AbstractSchema Conclusion Pharmacokinetic profile of the base-excision repair inhibitor Methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous.
Optimization of Preclinical Animal Models Steven Perrin, PhD CEO, CSO ALS Therapy Development Institute.

Optimization of Preclinical Animal Models Steven Perrin, PhD CEO, CSO ALS Therapy Development Institute.
Martha J. Morrell MD NeuroPace, Inc.

Martha J. Morrell MD NeuroPace, Inc.
Advancing the Development of Pediatric Therapeutics (ADEPT) II: Evaluation of Long-term Neurocognitive Development in Pediatrics U.S. Food and Drug Administration.

Advancing the Development of Pediatric Therapeutics (ADEPT) II: Evaluation of Long-term Neurocognitive Development in Pediatrics U.S. Food and Drug Administration.
JMV 1843 pharmacological profile

JMV 1843 pharmacological profile
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
What Do Toxicologists Do?

What Do Toxicologists Do?
ANTICONVULSANT DRUGS Edward D. French, Ph.D. Department of Pharmacology University of Arizona College of Medicine.

ANTICONVULSANT DRUGS Edward D. French, Ph.D. Department of Pharmacology University of Arizona College of Medicine.
TRANSLATIONAL RESEARCH New Therapies for MS Dennis Bourdette, M.D. and Arthur A. Vandenbark, Ph.D. TCR peptide therapy Recombinant TCR ligand (RTL) therapy.

TRANSLATIONAL RESEARCH New Therapies for MS Dennis Bourdette, M.D. and Arthur A. Vandenbark, Ph.D. TCR peptide therapy Recombinant TCR ligand (RTL) therapy.
© 2014 Direct One Communications, Inc. All rights reserved. 1 New Insights into the Basic Mechanisms, Diagnosis, and Staging of Epilepsy Nicole Odom, MD.

© 2014 Direct One Communications, Inc. All rights reserved. 1 New Insights into the Basic Mechanisms, Diagnosis, and Staging of Epilepsy Nicole Odom, MD.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Drug Discovery Process

Drug Discovery Process
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.

Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center 1-13-04.

INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
Strategy 2: Make the tissue more resilient to poor plumbing. Pros: -Likely a pharmacological treatment -Can be administered more quickly by 1 st response.

Strategy 2: Make the tissue more resilient to poor plumbing. Pros: -Likely a pharmacological treatment -Can be administered more quickly by 1 st response.

Similar presentations

Ads by Google